SPET in cardiology: Diagnosis, prognosis, and management of patients with coronary artery disease

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 49, Issue 2, 2005, Pages 193-203

  Tamaki, N ^a   Morita, K ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Coronary circulation; Myocardial ischemia; Tomography, emission computed

Indexed keywords

CARDIOLOGY; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; METHODOLOGY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOLOGY; CORONARY ARTERIOSCLEROSIS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33749319507     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 2000;101:1465-78.
2. Lee TH, Boucher CA. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001;344:1840-5.
3. 99mTc]TBI): initial experience in the human. J Nucl Med 1984;25:1350-5.
4. 99mTc]-methoxy-isobutyl-isonitrile (MIBI): comparison of short and long time intervals between rest and stress injections. Eur J Nucl Med 1988;13:515-22.
5. 99mTc] 2-methoxy-isobutyl-isonitrile: a direct comparison in normal individuals and patients with coronary artery disease. Circulation 1989;79:1282-93.
6. Wackers FJT, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-11.
7. Tamaki N, Takahashi N, Kawamoto M, Torizuka T, Tadamura E, Yonekura Y et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease. J Nucl Med 1994; 35: 594-600
8. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T et al. Comparison of defect size between thallium-201 and technetium-99m tetrofosmin myocardial single-photon emission computed tomography in patients with single-vessel coronary artery disease. Am J Cardiol 1996;77:350-4. (Pubitemid 26061164)
9. Iskandrian AS, Heo J, Kong B, Lyons E, Marsch S. Use of technetium-99m isonitrile (RP-30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease, and comparison with coronary arteriography and exercise thallium-201 SPET imaging. Am J Cardiol 1989;64:270-5.
10. 99mTc] sestamibi SPET imaging (perfusion and ECG-gated SPET) in detecting coronary artery disease in women. J Am Coll Cardiol 1997;29:69-77.
11. 99mTc] sestamibi uptake during adenosine-induced vasodilation as a function of coronary stenosis severity. Circulation 1995;91:813-20.
12. Maddahi J, Kiat H, Friedman JD et al. Technetium-99m-sestamibi myocardial perfusion imaging for evaluation of coronary artery disease. In: Zaret BL, Beller GA, editors. Nuclear cardiology: state of the art and future directions. ST Louis: Mo Mosby-Year Book; 1993p.191-200.
13. Berman DS, Kiat H, Friedman JD, Wang FP, van Train K, Matzer L et al. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study. J Am Coll Cardiol 1993;22:1455-64.
14. O'Keefe JH, Barnhart CS, Bateman TM. Comparision of stress echocardiography and stress myocardial perfusion scintigraphy for diagnosing coronary artery disease and assessing its severity. Am J Cardiol 1995;75:25D-34D.
15. Iskandrian AE, Heo J, Nallamothu N. Detection of coronary artery disease in women with use of stress single-photon emission computed tomography myocardial perfusion imaging. J Nucl Cardiol 1997;4:329-35.
16. DePuey EG, Krawczynska EG, Robbins WL. Thallium-201 SPET in coronary artery disease patients with left bundle branch block. J Nucl Med 1988;29:1479-85.
17. Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 1993;21:1583-90.
18. Gianrossi R, Detrano R, Mulvihill D, Lehmann K, Dubach P, Colombo A et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989;80:87-98.
19. Manning F, Morgan-Manning MG. Gated SPET with technetium-99m-sestamibi for assessment of myocardial perfusion abnormalities. J Nucl Med 1993;34:601-8.
20. 99mTc] MIBI emission tomography and by magnetic resonance imaging. Eur J Nucl Med 1996;23:909-16.
21. Williams KA, Taillon LA. Left ventricular function in patients with coronary artery disease assessed by gated tomographic myocardial perfusion images. J Am Coll Cardiol 1996;27:173-81.
22. Smanio PE, Watson DD, Segalla DL, Vinson EL, Smith WH, Beller GA. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol 1997;30:1687-92.
23. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPET. J Nucl Med 1995;36:2138-47.
24. Chua T, Kiat H, Germano G, Maurer G, van Train K, Friedman J et al. Gated technetium-99m sestamibi for simultaneous assessment of stress myocardial perfusion, postexercise regional ventricular function and myocardial viability. Correlation with echocardiography and rest thallium-201 scintigraphy. J Am Coll Cardiol 1994;23:1107-14.
25. Germano G, Erel J, Lewin H, Kavanagh PB, Berman DS. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1997;30:1360-7.
26. Christian TF, Clements IP, Gibbons RJ. Noninvasive identification of myocardium at risk in patients with acute myocardial infarction and nondiagnostic electrocardiograms with technetium-99m sestamibi. Circulation 1991;83:1615-20.
27. Bilodeau L, Theroux P, Gregoire J, Gagnon D, Arsenault A. Technetium-99m sestamibi tomography in patients with spontaneous chest pain: correlations with clinical, electrocardiographic and angiographic findings. J Am Coll Cardiol 1991;18:1684-91.
28. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:25A-30A.
29. Lee KL, Pryor DB, Pieper KS, Harrell FE Jr, Califf RM, Mark DB et al. Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. Circulation 1990;82:1705-17.
30. Iskandrian AS, Hakki AH, Kane-Marsch S. Prognostic implications of exercise thallium-201 scintigraphy in patients with suspected or known coronary artery disease. Am Heart J 1985;110:135-43.
31. Kaul S, Lilly DR, Gascho JA, Watson DD, Gibson RS, Oliner CA et al. Prognostic utility of the exercise thallium-201 test in ambulatory patients with chest pain: comparison with cardiac catheterization. Circulation 1988;77:745-58.
32. Palmas W, Friedman JD, Diamond GA, Silber H, Kiat H, Berman DS. Incremental value of simultaneous assessment of myocardial function and perfusion with technetium-99m sestamibi for prediction of extent of coronary artery disease. J Am Coll Cardiol 1995;25:1024-31.
33. Nallamouthu N, Araujo L, Russell J, Heo J, Iskandrian AE. Prognostic value of simultaneous perfusion and function assessment using technetium-99m sestamibi. Am J Cardiol 1996;78:562-4.
34. Brown KA, Boucher CA, Okada RD, Guiney TE, Newell JB, Strauss HW et al. Prognostic value of exercise thallium-201 imaging in patients presenting for evaluation of chest pain. J Am Coll Cardiol 1983;1:994-1001.
35. Pollock SG, Abbott RD, Boucher CA, Beller GA, Kaul S. Independent and incremental prognostic value of tests performed in hierarchical order to evaluate patients with suspected coronary artery disease. Validation of models based on these tests. Circulation 1992;85:237-48.
36. Iskandrian AS, Chae SC, Heo J, Stanberry CD, Wasserleben V, Cave V. Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPED thallium imaging in coronary artery disease. J Am Coll Cardiol 1993;22:665-70.
37. Machecourt J, Longere P, Fagret D, Vanzetto G, Wolf JE, Polidori C et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. Study in 1,926 patients with follow-up at 33 months. J Am Coll Cardiol 1994;23:1096-106.
38. Iskander S, ISkandrian AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 1998;32:57-62.
39. Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, Wang FP et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1995;26:639-47. Erratum in: J Am Coll Cardiol 1996;27:756.
40. Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, Friedman J et al. Exercise myocardial perfusion SPET in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996;93:905-14.
41. Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller GV et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study Group. J Am Coll Cardiol 1999;33:661-9.
42. Brown KA. Prognostic value of myocardial perfusion imaging: state of the art and new developments. J Nucl Cardiol 1996;3:516-37.
43. Verani MS. Risk stratifying patients who survive an acute myocardial infarction. J Nucl Cardiol 1998;5:96-108.
44. 99mTc]-hexakis-2-methoxy-2- methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 1989;80:1277-86.
45. Pohost GM, Zir LM, Moore RH, McKusick KA, Guiney TE, Beller GA. Differentiation of transiently ischemic from infarcted myocardium by serial imaging after single dose of thallium-201. Circulation 1977;55:294-302.
46. Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-6.
47. Tamaki N, Ohtani H, Yamashita K, Magata Y, Yonekura Y, Nohara R et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991;32:673-8.
48. Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM, Bacharach SL, Dilsizian V. Stress-induced reversible and mild-to-moderate irreversible thallium defects: are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998;98:501-8.
49. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T et al. Significance of late redistribution thallium-201 imaging after rest injection for detection of viable myocardium. J Nucl Med 1997;38:1073-8.
50. 201Tl in a model of acute coronary reperfusion. Circulation 1996;94:2605-13.
51. Cuocolo A, Pace L, Ricciardelli B, Chiariello M, Trimarco B, Salvatore M. Identification of viable myocardium in patients with chronic coronary artery disease: comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile. J Nucl Med 1992;33:505-11.
52. 99mTc] sestamibi. Circulation 1994;89:2552-61.
53. Sawada SG, Allman KC, Muzik O, Beanlands RS, Wolfe ER Jr, Gross M et al. Positron emission tomography detects evidence of viabUity in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994;23:92-8.
54. 99mTc] sestamibi with thallium reinjection and [18F]fluorodeoxyglucose. Circulation 1994;89:578-87. Erratum in: Circulation 1995;91:3026.
55. Matsunari I, Taki J, Nakajima K, Tonami N, Hisada K. Myocardial viability assessment using nuclear imaging. Ann Nucl Med 2003;17:169-79.
56. Mabuchi M, Kubo N, Morita K, Makino Y, Matsui Y, Murashita T et al. Prediction of functional recovery after coronary bypass surgery using quantitative gated myocardial perfusion SPET. Nucl Med Commun 2003;24:625-31.
57. Yoshinaga K, Monta K, Yamada S, Komuro K, Katoh C, Ito Y et al. Low-dose dobutamine electrocardiograph-gated myocardial SPET for identifying viable myocardium: comparison with dobutamine stress echocardiography and PET. J Nucl Med 2001;42:838-44.
58. Yoshinaga K, Katoh C, Noriyasu K, Yamada S, Ito Y, Kuge Y et al. Low-dose dobutamine stress gated SPET for identification of viable myocardium: comparison with stress-rest perfusion SPET and PET. Eur J Nucl Med Mol Imaging 2002;29:882-90.
59. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451-60.
60. Neely JR, Rovetto M, Oram J. Mocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972;15:289-329.
61. Liedke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;23:321-36.
62. Bax JJ, Visser FC, Blanksma PK, Veening MA, Tan ES, Willemsen TM et al. Comparison of myocardial uptake of fluorine-18-fluorod-eoxyglucose imaged with PET and SPET in dyssynergic myocardium. J Nucl Med 1996;37:1631-6.
63. Mabuchi M, Kubo N, Morita K, Noriyasu K, Itoh Y, Katoh C et al. Value and limitation of myocardial fluorodeoxyglucose single photon emission computed tomography using ultra-high energy collimators for assessing myocardial viability. Nucl Med Commun 2002;23:879-85.
64. Sandler MP, Videlefsky S, Delbeke D, Patton JA, Meyerowitz C, Martin WH et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995;26:870-8.
65. Tamaki N, Morita K, Kuge Y, Tsukamoto E. The role of fatty acids in cardiac imaging. J Nucl Med 2000;41:1525-34.
66. Knapp FF, Kropp J. Iodine-123-labeled fatty acids for myocardial single-photon emission tomography. Eur J Nucl Med 1995;22:361-81.
67. Ambrose KR, Owen BA, Goodman MM, Knapp FF Jr. Evaluation of the metabolism in rat heart of two new radioiodinated 3-methyl-branched fatty acid myocardial imaging agents. Eur J Nucl Med 1987;12:486-91.
68. Nohara R, Okuda K, Ogino M, Hosokawa R, Tamaki N, Konishi J et al. Evaluation of myocardial viability with iodine-123-BMIPP in a canine model. J Nucl Med 1996;37:1403-7.
69. Tamaki N, Kawamoto M. The use of iodinated free fatty acids for assessing fatty acid metabolism. J Nucl Cardiol 1994;1:S72-8.
70. Tamaki N, Tadamura E, Kawamoto M, Magata Y, Yonekura Y, Fujibayashi Y et al. Decreased uptake of iodinated branched fatty acid analog indicates metabolic alterations in ischemic myocardium. J Nucl Med 1995;36:1974-80.
71. Tamaki N, Kawamoto M, Yonekura Y, Fujibayashi Y, Takahashi N, Konishi J et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992;33:659-67.
72. 123I fatty acid and thallium-201 to assess ischemic myocardium. Ann Nucl Med 1994;8:47-54.
73. Matsunari I, Saga T, Taki J, Akashi Y, Hirai J, Wakasugi T et al. Kinetics of iodine-123-BMIPP in patients with prior myocardial infarction: assessment with dynamic rest and stress images compared with stress thallium-201 SPET. J Nucl Med 1994;35:1279-85.
74. Tawarahara K, Kurata C, Taguchi T, Aoshima S, Okayama K, Kobayashi A et al. Simultaneous dual myocardial imaging with iodine-123-beta-methyl iodophenyl-pentadecanoic acid (BMIPP) and thallium-201 in patients with coronary heart disease. Jpn Circ J 1994;58:107-15.
75. 201Tl SPET images. Eur J Nucl Med 1996;23:917-23.
76. Hashimoto A, Nakata T, Tsuchihashi K, Tanaka S, Fujimori K, Iimura O. Postischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am J Cardiol 1996;77:25-30.
77. Matsunari I, Saga T, Taki J, Akashi Y, Hirai J, Wakasugi T et al. Improved myocardial fatty acid utilization after percutaneous transluminal coronary angioplasty. J Nucl Med 1995;36:1605-7.
78. 123I-β-methyl-iodophenyl pentadecanoic acid. Eur J Nucl Med 1994;21:283-91.
79. Franken PR, De Geeter F, Dendale P, Demoor D, Block P, Bossuyt A. Abnormal free fatty acid uptake in subacute myocardial infarction after coronary thrombolysis: correlation with wall motion and inotropic reserve. J Nucl Med 1994;35:1758-65.
80. Franken PR, Dendale P, De Geeter F, Demoor D, Bossuyt A, Block P. Prediction of functional outcome after myocardial infarction using BMIPP and sestamibi scintigraphy. J Nucl Med 1996;37:718-22.
81. Tsubokawa A, Lee JD, Shimizu H, Nakano A, Uzui H, Takeuchi M et al. Recovery of perfusion, glucose utilization and fatty acid utilization in stunned myocardium. J Nucl Med 1997;38:1835-7.
82. 123I-BMIPP for the diagnosis of coronary artery disease: application to patients with diabetes mellitus and hyperlipidaemia. Nucl Med Commun 1996;17:675-80.
83. Taki J, Nakajima K, Matsunari I, Bunko H, Takada S, Tonami N. Impairment of regional fatty acid uptake in relation to wall motion and thallium-201 uptake in ischaemic but viable myocardium: assessment with iodine-123-labelled beta-methyl-branched fatty acid. Eur J Nucl Med 1995;22:1385-92.
84. 123I-BMIPP scintigraphy for detection of organic coronary stenosis and therapeutic outcome in patients with chest pain. Ann Nucl Med 2000;14:187-92.
85. Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 2001;38:1888-94.
86. Nakata T, Kobayashi T, Tamaki N, Kobayashi H, Wakabayashi T, Shimoshige S et al. Prognostic value of impaired myocardial fatty acid uptake in patients with acute myocardial infarction. Nucl Med Commun 2000;21:897-906.
87. Tamaki N, Tadamura E, Kudoh T, Hattori N, Yonekura Y, Nohara R et al. Prognostic value of iodine-123 labelled BMIPP fatty acid analogue imaging in patients with myocardial infarction. Eur J Nucl Med 1996;23:272-9.
88. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
89. Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhthmogenic. Circulation 1987;75:877-87
90. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
91. 123I meta-iodobenzylguanidine. J Nucl Med 1981;22:129-32.
92. Dae MW, Herre JM, O'Connell JW, Botvinick EH, Newman D, Munoz L. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 1991;17:1416-23.
93. Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989;14:1519-26.
94. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
95. 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 1990;119:1329-37.
96. Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 1996;37:1985-90.
97. Gohl K, Feistel H, Weikl A, Bachmann K, Wolf F. Congenital myocardial sympathetic dysinnervation (CMSD): a structural defect of idiopathic long QT syndrome. Pacing Clin Electrophysiol 1991;14: 1544-53.
98. 123I-meta- iodobenzylguanidine scintigraphy. Circulation 1994;89:667-83.
99. Rabinovitch MA, Rose CP, Schwab AJ, Fitchett DH, Honos GN, Stewart JA et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
100. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.